Global life sciences venture capital firm SV Life Sciences has held the first close of its latest fund at $273.5m.
According to a regulatory document filed with the SEC, the fund was subscribed by 24 investors. The form lists managing partners Kate Bingham, James Garvey, Tom Flynn, Eugene Hill, Paul LaViolette, David Milne and Michael Ross as people related with the offering.
The vehicle has a final target of $400m.
With a team of 34 working in offices in Boston, London, and San Francisco, SV Life Sciences invests between $1m and $40m in biotechn/biopharma, medical device and healthcare services companies.
The firm, which has invested in over 160 companies to date, also manages the $100M Dementia Discovery Fund (DDF), a recently launched global investment fund that supports discovery and development of novel dementia treatments.